Enjoy complimentary customisation on priority with our Enterprise License!
The herpes treatment market size is forecast to increase by USD 1.14 billion at a CAGR of 4.43% between 2023 and 2028. The market's growth is driven by several factors, including the rising prevalence of herpes infections, the expanding patient pool, and the increasing incidence of shingles among the older population. The growing awareness about these conditions and advancements in diagnostic technologies also contribute to market expansion. Additionally, increased healthcare spending and the development of more effective antiviral treatments are boosting market growth. Countries like the United States, China, and Germany are at the forefront, with their robust healthcare infrastructures supporting higher diagnosis and treatment rates. As a result, the demand for herpes and shingles treatments is expected to continue rising, further propelling market growth. It also includes an in-depth analysis of market trends and analysis, market growth analysis and challenges. Furthermore, the report includes historic market data from 2018 - 2022.
To learn more about this report, View Report Sample
The Market encompasses various interventions for managing Herpes Simplex Virus (HSV) infections, including antiviral drugs and vaccines. Genital herpes infections, caused by HSV-1 and HSV-2, are a significant health concern worldwide. Antiviral drugs, such as Acyclovir, Valacyclovir, and Famciclovir, are commonly used for treating both oral and genital herpes infections. These medications inhibit the virus from replicating, reducing the severity and duration of symptoms. Phase 1/2 clinical trials are ongoing for developing new therapeutic approaches, including gene therapy and mRNA therapeutics, to tackle HSV infections more effectively. HSV infections can be transmitted through saliva, vaginal secretions, and semen, making prevention and treatment crucial for the hospital population. The market is driven by the increasing healthcare expenditure and the growing need for effective antiviral drugs and potential vaccines against Varicella-zoster viruses. Our researchers analyzed the market research and growth data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Increasing prevalence of herpes infection drives the market growth. The Market, particularly the HSV-2 segment, experiences significant growth due to the increasing prevalence of herpes, especially among individuals with weakened immune systems. Factors contributing to this vulnerability include organ transplant recipients, HIV or AIDS positive individuals, cancer patients undergoing chemotherapy, and those on long-term corticosteroid usage.
Despite advancements in organ transplantation, herpesvirus infections remain a significant challenge for transplant recipients, leading to morbidity and mortality. In response, the market witnesses ongoing innovation, with companies such as Gilead Sciences and Assembly Biosciences spearheading developments. Notable advancements include the use of mRNA technology in the form of RVx-201, which holds the ILAP designation from the MHRA Innovation Passport. Hence, such factors are driving the market during the forecast period.
Emergence of novel therapies is a primary trend in the market. The market, particularly the HSV-2 segment, faces a significant reliance on a restricted range of therapies. Currently, there is no cure for genital and oral herpes; treatment solely manages the symptoms. Famciclovir, Valacyclovir, and Acyclovir are major drugs used to control genital herpes outbreaks.
However, they do not prevent shedding. To address this challenge, research is ongoing to develop innovative treatment options. For instance, Genocea's GEN-003 vaccine, under clinical trials, has shown promise in controlling both shedding and outbreaks of HSV-2 infection. In the oral segment, Gilead Sciences and Assembly Biosciences are key players. Hence, such factors are driving the market during the forecast period.
Highly genericized market is a major challenge hindering the market. The market, particularly the HSV-2 segment, experiences significant competition due to the introduction of generic alternatives. With patent expiries, drugs such as Famciclovir, Valacyclovir, and Acyclovir have seen increased market penetration. This trend is supported by various organizations, both governmental and non-profit, aiming to reduce pharmaceutical costs.
The affordability of these generics has intensified industry competition, impacting the revenue of branded drug companies. In Europe and several US states, generic substitution has been implemented to boost the use of generic medicines and decrease overall pharmaceutical costs. Key players in the oral segment, including Gilead Sciences and Assembly Biosciences, face this competition. Hence, such factors are hindering the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbvie Inc - The company offers herpes treatment called RINVOQ as monotherapy or with topical corticosteroid applications.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
By Product
The herpes simplex virus treatment market share growth by the vaccination segment will be significant during the forecast period. The market encompasses various interventions, including antiviral medications like Acyclovir Oral Suspension, and the exploration of innovative approaches such as gene therapy and mRNA therapeutics. Acyclovir and its derivatives, Famciclovir and Valacyclovir, are commonly used for managing herpes simplex virus (HSV) infections caused by HSV-1 and HSV-2. These infections can manifest in different forms, including herpetic gingivostomatitis, and can lead to symptoms such as odynophagia and irritation in the saliva, vaginal secretion, and semen.
Get a glance at the market contribution of various segments View the PDF Sample
The vaccination segment was valued at USD 2.11 billion in 2018 and continued to grow by 2022. Genetic retinal diseases, such as herpes simplex virus retinitis, pose a significant challenge in the field of ophthalmology. Rational Vaccines, a biotech company, is currently conducting a Phase 1/2 clinical trial for RVx-001-PSS, a live-attenuated vaccine for preventing HSV-1 and HSV-2 infections. Another company, Virios Therapeutics, is developing IMC-1, a subunit vaccine for fibromyalgia and irritable bowel syndrome, which are often associated with HSV infections. The retail pharmacy sector plays a crucial role in the distribution of over-the-counter (OTC) products. Healthcare expenditure on it is influenced by reimbursement policies and the availability of generics. Hence, such factors are fuelling the growth of this segment which in turn drives the market during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The market in the North American region is primarily driven by the demand for drugs and vaccines used in the management of Oral herpes, caused by HSV-1 infection, and Genital herpes, caused by HSV-2 infection. Acyclovir Oral Suspension is a widely used antiviral medication for the treatment of herpes. The market's growth is also fueled by the increasing prevalence of herpes among the geriatric population due to weakened immune systems. Complications such as Postherpetic Neuralgia (PHN) and fibromyalgia further necessitate effective treatment options. In the pipeline, Rational Vaccines' RVx-001-PSS is undergoing Phase 1/2 clinical trials for the prevention of HSV-1 and HSV-2 infections. Virios Therapeutics' IMC-1 is another potential treatment for herpes, targeting the latent form of the virus. Fibromyalgia and Irritable bowel syndrome, often co-occurring with herpes, add to the healthcare expenditure. Retail pharmacies stock Over-the-counter (OTC) products like Lidocaine and Benzocaine for symptomatic relief. Hence, such factors are driving the market growth in North America during the forecast period.
Segment Overview
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The market encompasses infectious conditions caused by the Herpes Simplex Virus (HSV). Herpes infections can manifest in various forms, including Herpes Simplex Virus Type 1 (HSV-1) and Herpes Simplex Virus Type 2 (HSV-2). The global market is significant, with a growing number of people seeking effective solutions. These treatments include antiviral drugs, vaccines, and supportive therapies. The market is driven by factors such as increasing awareness and diagnosis rates, rising prevalence of the disease, and the development of new and innovative treatments. Additionally, the market is fueled by demographic shifts, including an aging population and a rise in sexual activity.
They are available in various forms, including oral medications, topical creams, and injectable therapies. Some of the leading companies in the Herpes market focus on research and development of new treatments, while others offer supportive therapies and educational resources. The market is expected to grow in the coming years, driven by increasing demand for effective treatments and a growing awareness of the disease. The market landscape depends on the Irish Journal of Medical Science, HSV-1 (Herpes Simplex Virus Type-1). The use of advanced technologies, such as gene therapy and vaccines, is also expected to contribute to market growth. Overall, the Herpes market is a dynamic and evolving industry, with a significant impact on public health and healthcare systems around the world. The development of new and innovative treatments, coupled with increasing awareness and education, is expected to drive market growth in the coming years.
Market Scope |
|
Report Coverage |
Details |
Page number |
171 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.43% |
Market growth 2024-2028 |
USD 1.14 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.17 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 40% |
Key countries |
US, Japan, Germany, France, and UK |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., AiCuris Anti infective Cures AG, Aurobindo Pharma Ltd., Avet Pharmaceuticals Inc., Bausch Health Companies Inc., CENTURION REMEDIES Pvt. Ltd., Cipla Inc., Eli Lilly and Co., Fresenius SE and Co. KGaA, Gilead Sciences Inc., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Zeelab Laboratories Ltd., and Zydus Lifesciences Ltd. |
Market dynamics |
Parent market analysis, Market forecast, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.